MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Scope & Guideline

Illuminating the Pathways of Genetic Change

Introduction

Welcome to the MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1386-1964
PublisherELSEVIER
Support Open AccessNo
Country-
TypeJournal
Convergefrom 1964 to 2024
AbbreviationMUTAT RES-FUND MOL M / Mutat. Res.-Fundam. Mol. Mech. Mutagen.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

The journal 'Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis' primarily aims to advance the understanding of mutagenesis, its molecular mechanisms, and implications in cancer biology and other genetic disorders. The journal encompasses a wide range of topics that explore the intricate relationships between genetic alterations, environmental factors, and disease progression.
  1. Molecular Mechanisms of Mutagenesis:
    The journal focuses on elucidating the fundamental molecular processes that lead to mutations, including the roles of DNA damage, repair mechanisms, and the influence of various biochemical pathways.
  2. Cancer Genetics and Mutagenesis:
    A significant emphasis is placed on the study of mutations in the context of cancer, exploring how genetic alterations contribute to tumor initiation, progression, and resistance to therapies.
  3. Impact of Environmental Factors:
    Research addressing the effects of environmental agents, such as chemicals and radiation, on mutagenesis is a core aspect, highlighting the interplay between external factors and genetic susceptibility.
  4. Innovative Techniques in Genomic Research:
    The journal encourages the use of cutting-edge methodologies, such as CRISPR/Cas9 gene editing, bioinformatics, and molecular dynamics simulations, to investigate mutagenesis and its implications.
  5. Translational Research and Therapeutic Strategies:
    There is a focus on translating basic research findings into clinical applications, aiming to identify potential biomarkers for cancer diagnosis and novel therapeutic targets.
Recent years have seen the emergence of several key themes within the journal, reflecting current trends in mutation research and its applications in cancer biology. These themes indicate a progressive shift towards more integrative and translational approaches.
  1. CRISPR/Cas9 Applications:
    The rise in publications utilizing CRISPR/Cas9 technology signifies a growing interest in gene editing as a tool for studying mutagenesis and developing therapeutic strategies.
  2. Role of Non-coding RNAs:
    There is an increasing focus on the involvement of non-coding RNAs, particularly microRNAs and long non-coding RNAs, in regulating gene expression and their implications in cancer progression and therapy.
  3. DNA Repair Mechanisms:
    Research exploring the intricacies of DNA repair pathways and their relationship to cancer susceptibility and treatment resistance is gaining traction, highlighting their importance in understanding mutagenesis.
  4. Environmental and Lifestyle Factors in Mutagenesis:
    Emerging studies investigating how lifestyle factors, such as diet and exposure to pollutants, influence mutagenesis and cancer risk, reflect an interdisciplinary approach to understanding genetic changes.
  5. Biomarkers for Cancer Diagnosis and Prognosis:
    There is a notable trend towards identifying novel biomarkers linked to mutational profiles that can aid in cancer diagnosis and predict treatment outcomes, showcasing the journal's relevance in clinical applications.

Declining or Waning

While the journal continues to cover a broad spectrum of topics related to mutagenesis, certain themes appear to be losing prominence in recent publications. This decline may reflect shifts in research interest or advancements in technology that have led to new focal areas.
  1. Traditional Chemical Mutagens:
    Research on classical chemical mutagens, such as alkylating agents and their mechanisms, has decreased, possibly due to the emergence of more complex models and the focus on genetic and environmental interactions.
  2. Basic Radiation Studies:
    Publications centered solely on the basic effects of radiation on DNA without integrating molecular or genomic analyses have become less frequent, indicating a shift towards more comprehensive studies.
  3. Classic Models of Mutagenesis:
    The use of traditional model organisms, such as bacteria for mutagenicity testing, shows a decline, as researchers increasingly utilize more sophisticated models that better replicate human disease contexts.

Similar Journals

ANTICANCER RESEARCH

Exploring Breakthroughs in Oncology and Medicine
Publisher: INT INST ANTICANCER RESEARCHISSN: 0250-7005Frequency: 12 issues/year

ANTICANCER RESEARCH, published by the International Institute of Anticancer Research, stands at the forefront of cancer-related scholarly communication. With ISSN 0250-7005 and E-ISSN 1791-7530, this esteemed journal has been serving the global research community since 1981, showcasing innovative research aimed at combating cancer through various therapeutic approaches and scientific inquiry. Based in Greece, the journal aims to disseminate vital findings in the fields of Cancer Research, Medicine, and Oncology, reflecting its notable categorization in the Q3 and Q2 quartiles as of 2023. Despite its rigorous peer-review process and the absence of open access, ANTICANCER RESEARCH remains a vital publication for researchers, clinicians, and students eager to stay updated on the evolving landscape of anticancer strategies. As it converges to its milestone year of 2024, the journal continues to enrich the discourse around cancer treatment and prevention, affirming its position as an essential resource for those dedicated to advancing knowledge in anticancer therapies.

Human Gene

Fostering Collaboration in Genetic Research
Publisher: ELSEVIERISSN: 2773-0441Frequency: 4 issues/year

Human Gene is an innovative open access journal published by ELSEVIER, dedicated to the ever-evolving field of genetics. Established in 2022, this journal serves as a vital resource for researchers, professionals, and students alike, aiming to facilitate the dissemination of groundbreaking research and advancements in both basic and clinical genetics. With an ISSN of 2773-0441, Human Gene focuses on providing a platform for high-quality studies that investigate genetic mechanisms, their implications in health and disease, and novel therapeutic strategies. The journal currently holds a Q4 ranking in both Genetics and Clinical Genetics categories, reflecting its emerging status within the scientific community, and strives to enhance its impact to better serve an engaged audience. With its base in Amsterdam, Netherlands, Human Gene is committed to making research accessible through its open access model, inviting contributions that advance our understanding of human genetics and foster collaboration across disciplines.

CANCER GENE THERAPY

Transforming Cancer Care Through Genetic Insights
Publisher: SPRINGERNATUREISSN: 0929-1903Frequency: 12 issues/year

Cancer Gene Therapy, published by SpringerNature, stands at the forefront of research in the fields of cancer research, molecular biology, and molecular medicine. With a robust impact factor reflecting its significant influence—ranking in the Q2 category for cancer research and Q1 for both molecular biology and molecular medicine—it serves as an essential resource for scholars and practitioners alike. Since its inception in 1994, the journal has dedicated itself to advancing the understanding and therapeutic application of genetic innovations in oncology. Notably, it holds distinguished Scopus ranks, placing it among the top tier journals in its categories, underscoring its importance to the scientific community. While open access options are not available, the compelling research published here offers invaluable insights into the latest advancements and strategies in cancer therapy. Engaging with *Cancer Gene Therapy* not only keeps professionals informed but also inspires future innovations in the quest for effective cancer treatments.

DNA AND CELL BIOLOGY

Unraveling the Mysteries of DNA and Cell Dynamics
Publisher: MARY ANN LIEBERT, INCISSN: 1044-5498Frequency: 12 issues/year

DNA AND CELL BIOLOGY, published by Mary Ann Liebert, Inc, is a distinguished journal in the realms of cell biology, genetics, and molecular biology, holding a notable position in its Q3 and Q2 quartile rankings across multiple academic categories as of 2023. With an ISSN of 1044-5498 and an E-ISSN of 1557-7430, this journal has been a pivotal platform for the dissemination of cutting-edge research since its inception in 1990, extending its coverage through 2024. Situated in the United States, the journal offers high-quality peer-reviewed articles, exploring significant advancements in biological sciences while fostering interdisciplinary collaborations within the research community. Though it currently does not offer open access, subscribed institutions and individual readers benefit from its rich repository of knowledge. The journal's rigorous standards and impactful content make it an essential resource for researchers, professionals, and students alike, aiming to stay at the forefront of discoveries influencing DNA and cellular dynamics.

Genetics Research

Exploring the Frontiers of Genetic Discovery
Publisher: HINDAWI LTDISSN: 0016-6723Frequency: 1 issue/year

Genetics Research, published by HINDAWI LTD, is a distinguished open access journal that has been at the forefront of genetic studies since its inception in 1960. With the transition to open access in 2019, this journal has expanded its accessibility, fostering knowledge dissemination across the global scientific community. Operating out of the United Kingdom, it provides a platform for innovative research in the fields of genetics and molecular biology, encompassing a broad range of topics that are highly relevant to medical sciences. As of 2023, it holds a Q4 classification in Genetics and a Q3 classification in miscellaneous Medicine, reflecting its ongoing commitment to scholarly excellence amidst shifting academic landscapes. While the journal's H-index remains unlisted, its indexed ranking within Scopus, with a rank of #325/328 in the Genetics category highlights the challenges ligated to its niche audience. Nevertheless, it serves as a crucial resource for researchers, professionals, and students eager to contribute to and stay informed on the latest genetic research trends and breakthroughs.

CELLULAR & MOLECULAR BIOLOGY LETTERS

Bridging Gaps in Cellular Research for a Global Audience
Publisher: BMCISSN: 1425-8153Frequency: 1 issue/year

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.

EXPERT REVIEWS IN MOLECULAR MEDICINE

Unraveling Molecular Mechanisms for Health Insights
Publisher: CAMBRIDGE UNIV PRESSISSN: 1462-3994Frequency: 1 issue/year

EXPERT REVIEWS IN MOLECULAR MEDICINE, published by Cambridge University Press, stands at the forefront of research in the fields of Molecular Biology and Molecular Medicine. With an impressive impact factor reflecting its Q1 status in both relevant categories, this journal serves as an essential platform for disseminating cutting-edge reviews and critical assessments that are vital for advancing our understanding of molecular mechanisms in health and disease. Established in 1997 and continuously evolving until 2024, it features contributions from leading experts that highlight emerging trends and innovative methodologies. Researchers, professionals, and students are encouraged to engage with the content, benefiting from the journal’s rigorous peer-review process and its commitment to academic excellence, making it a valuable resource within the scientific community.

Molecular & Cellular Oncology

Exploring the cellular mechanisms of oncogenesis.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

Cell Journal

Advancing the Frontiers of Cell Science
Publisher: ROYAN INSTISSN: 2228-5806Frequency: 12 issues/year

Cell Journal is a leading interdisciplinary publication in the fields of Cell Biology, Developmental Biology, Molecular Biology, and Reproductive Medicine, published by ROYAN INST since its inception as an open-access journal in 2007. With an ISSN of 2228-5806 for print and 2228-5814 for electronic editions, it provides a vital platform for researchers and professionals to disseminate innovative findings and insights that shape our understanding of cellular processes and reproductive sciences. The journal boasts an impressive Scopus ranking, achieving a Q3 position in both Molecular Biology and Reproductive Medicine, highlighting its significance in the academic community. Situated in Tehran, Iran, Cell Journal encourages global collaboration through its accessible content, making cutting-edge research available to a diverse audience. As it converges from 2011 to 2024, the journal continues to emphasize the importance of thorough scientific inquiry, fostering advancements that drive both theoretical frameworks and practical applications in cell science.

INTERNATIONAL JOURNAL OF ONCOLOGY

Illuminating the path to effective cancer therapies.
Publisher: SPANDIDOS PUBL LTDISSN: 1019-6439Frequency: 12 issues/year

INTERNATIONAL JOURNAL OF ONCOLOGY is a leading academic publication dedicated to advancing the field of cancer research and treatment. Published by SPANDIDOS PUBL LTD in Greece, this journal, with ISSN 1019-6439 and E-ISSN 1791-2423, has established itself as a reputable source of peer-reviewed articles since its inception in 1993. With an impressive Q2 ranking in both Cancer Research and Oncology categories, as well as high Scopus ranks reflecting its significant contribution to the fields of Medicine and Biochemistry, the journal offers a platform for researchers, clinicians, and students alike to disseminate their findings and engage in dialogue surrounding innovative practices and breakthroughs. Although the journal follows a traditional subscription model, it continues to attract a diverse readership interested in the latest developments in oncological research, providing essential insights into cancer biology, therapeutics, and patient care. With a commitment to excellence, the INTERNATIONAL JOURNAL OF ONCOLOGY plays a vital role in shaping the future of oncology research and is a must-read for anyone passionate about advancing cancer treatment and prevention.